Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease…
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE…
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or…
Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
December 09, 2024 12:05 ET | Source: Tessera Therapeutics In vivo proof-of-concept…
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT…
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Associations 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:…
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson’s Disease Patients
HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE…
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (arimoclomol) for Treatment of Niemann-Pick Disease Type C
November 21, 2024 16:51 ET | Source: Zevra Therapeutics MIPLYFFA, the first…
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers Disease
November 20, 2024 07:00 ET | Source: Voyager Therapeutics, Inc. - Candidate…
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of…